Literature DB >> 25485042

A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA.

Sameer K Nath1, Zhe J Chen1, Bryan P Rowe1, Rachel C Blitzblau2, Sanjay Aneja1, Baiba J Grube3, Nina R Horowitz3, Joanne B Weidhaas1.   

Abstract

OBJECTIVES: (a) To prospectively determine if multidwell position dose delivery can decrease skin dose and resultant toxicity over single dwell balloon-catheter partial breast irradiation, and (b) to evaluate whether specific skin parameters could be safely used instead of skin-balloon distance alone for predicting toxicity and treatment eligibility.
METHODS: A single-arm phase II study using a Simon two-stage design was performed on 28 women with stage 0-II breast cancer. All patients were treated with multiple dwell position balloon-catheter brachytherapy. The primary endpoint was ≥ grade 2 skin toxicity. Initial entry required a balloon-skin distance ≥ 7 mm. Based on the toxicity in the first 16 patients, additional patients were treated irrespective of skin-balloon distance as long as the Dmax to 1 mm skin thickness was < 130%.
RESULTS: Compared to the phantom single dwell plans, multidwell planning yielded superior PTV coverage as per median V90, V95 and V100, but had slightly worse V150, V200 and DHI. Dmax to skin was decreased by multidwell planning at multiple skin thicknesses. The most common acute toxicity was grade 1 erythema (57%), and only two patients (7%) developed acute grade 2 toxicity (erythema). Late grade 1 fibrosis was seen in 32%. No patients experienced grade 3, 4, or 5 toxicity.
CONCLUSIONS: Multidwell position planning for balloon-catheter brachytherapy results in lower skin doses with equal to superior PTV coverage and an overall low rate of initial skin toxicity. Our data suggest that limiting the Dmax to < 130% to 1 mm thick skin is achievable and results in minimal toxicity.

Entities:  

Keywords:  MammoSite; accelerated partial breast irradiation; brachytherapy; breast cancer; skin toxicity

Year:  2014        PMID: 25485042      PMCID: PMC4254816          DOI: 10.1007/s13566-014-0153-8

Source DB:  PubMed          Journal:  J Radiat Oncol        ISSN: 1948-7908


  16 in total

1.  Improvements in critical dosimetric endpoints using the Contura multilumen balloon breast brachytherapy catheter to deliver accelerated partial breast irradiation: preliminary dosimetric findings of a phase iv trial.

Authors:  Douglas W Arthur; Frank A Vicini; Dorin A Todor; Thomas B Julian; Maureen R Lyden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-06       Impact factor: 7.038

2.  Individual variation and dose dependency in the progression rate of skin telangiectasia.

Authors:  I Turesson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-12       Impact factor: 7.038

3.  Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation.

Authors:  Frank Vicini; Peter Beitsch; Coral Quiet; Mark Gittleman; Vic Zannis; Ricky Fine; Pat Whitworth; Henry Kuerer; Bruce Haffty; Martin Keisch; Maureen Lyden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-14       Impact factor: 7.038

4.  First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial.

Authors:  Frank A Vicini; Peter D Beitsch; Coral A Quiet; Angela Keleher; Delia Garcia; Howard C Snider; Mark A Gittleman; Victor J Zannis; H Kuerer; Eric B Whitacre; Pat W Whitworth; Richard E Fine; Bruce G Haffty; L Stacey Arrambide
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

5.  Accelerated partial breast irradiation via brachytherapy: a patterns-of-care analysis with ASTRO consensus statement groupings.

Authors:  Zain A Husain; Usama Mahmood; Alexandra Hanlon; Geoffrey Neuner; Robert Buras; Katherine Tkaczuk; Steven J Feigenberg
Journal:  Brachytherapy       Date:  2011-06-12       Impact factor: 2.362

6.  Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy registry trial.

Authors:  A J Khan; Douglas Arthur; F Vicini; P Beitsch; H Kuerer; S Goyal; Maureen Lyden; B G Haffty
Journal:  Ann Surg Oncol       Date:  2011-11-23       Impact factor: 5.344

7.  Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: a pathologic analysis.

Authors:  Frank A Vicini; Larry L Kestin; Neal S Goldstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

8.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

9.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.

Authors:  Umberto Veronesi; Natale Cascinelli; Luigi Mariani; Marco Greco; Roberto Saccozzi; Alberto Luini; Marisel Aguilar; Ettore Marubini
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

Review 10.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Authors:  S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto
Journal:  Lancet       Date:  2011-10-19       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.